Pharscin Pharma announced that the company recently received the "Drug Re-registration Approval Notice" issued by the Chongqing Municipal Drug Administration for three of its drugs. The drugs included in the re-registration approval notice are Ganju Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets. Ganju Bingmei Tablets are used for loss of voice and acute pharyngitis caused by wind-heat invading the lungs, Liuwei Anshen Capsules are used for insomnia classified as Yin deficiency with excessive fire and phlegm according to traditional Chinese medicine, and Silotazol Tablets are used to improve ischemic symptoms such as ulcers, limb pain, cold sensation, and intermittent claudication caused by chronic arterial occlusive disease, as well as to prevent the recurrence of cerebral infarction